DYNAVAX TECHNOLOGIES CORP (DVAX) Covered Calls

DYNAVAX TECHNOLOGIES CORP covered calls Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases.

You can sell covered calls on DYNAVAX TECHNOLOGIES CORP to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DVAX (prices last updated Mon 4:16 PM ET):

DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
13.22 -0.08 12.95 13.35 847K - 0.8B
Covered Calls For DYNAVAX TECHNOLOGIES CORP (DVAX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Aug 17 13 0.40 12.95 0.4% 29.2%
Sep 21 13 0.90 12.45 4.4% 40.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor TLR biology to discover and develop novel vaccines and therapeutics. The company's development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company's other products under pipeline are SD-101, DV1179 Autoimmune Disease and AZD1419 Asthma Therapy. Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.